This is how you did:
Kyprolis, the multiple myeloma drug Amgen acquired with its $10 billion purchase of Onyx Pharmaceuticals, had sales of $91 million, falling short of Wall Street estimates of $109 million.
This is how we did:
Enbrel sales rose 11 percent in the quarter to $1.34 billion, topping analyst expectations of $1.21 billion.
Sales of Amgen’s osteoporosis drugs again improved thanks to stronger volume. Prolia revenue climbed by a third to $315 million, while XGeva sales jumped 14% to $325 million.
WHO BRINGS IS MORE MONEY? AMGENITES
WHO FELL SHORT? ONYX
WHO CAN SELL? AMGEN AMGEN AMGEN!!!!
Kyprolis, the multiple myeloma drug Amgen acquired with its $10 billion purchase of Onyx Pharmaceuticals, had sales of $91 million, falling short of Wall Street estimates of $109 million.
This is how we did:
Enbrel sales rose 11 percent in the quarter to $1.34 billion, topping analyst expectations of $1.21 billion.
Sales of Amgen’s osteoporosis drugs again improved thanks to stronger volume. Prolia revenue climbed by a third to $315 million, while XGeva sales jumped 14% to $325 million.
WHO BRINGS IS MORE MONEY? AMGENITES
WHO FELL SHORT? ONYX
WHO CAN SELL? AMGEN AMGEN AMGEN!!!!
Team Onyx....
Aucun commentaire:
Enregistrer un commentaire